Study supports link between injectable hormonal contraceptive and HIV riskBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h112 (Published 09 January 2015) Cite this as: BMJ 2015;350:h112
- Jacqui Wise
A meta-analysis has found that women who use depot medroxyprogesterone acetate, commonly known by its brand name Depo-Provera, have a moderately raised risk of becoming infected with HIV.1 The study, published in The Lancet Infectious Diseases, found that the risk was not increased among users of oral contraceptive pills, combined oral contraceptives, or norethisterone enantate.
Researchers from the University of California at Berkeley looked at data from 12 observational studies in sub-Saharan Africa involving 39 560 women. Use of depot medroxyprogesterone acetate was found to increase a woman’s risk of acquiring HIV by 40% (pooled hazard ratio 12.40 (95% confidence interval 1.16 to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial